{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:30:03Z","timestamp":1772163003888,"version":"3.50.1"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mSphere"],"published-print":{"date-parts":[[2020,4,29]]},"abstract":"<jats:p>\n                    Laboratory surveillance of invasive meningococcal disease (IMD) is important to our understanding of the evolving nature of the\n                    <jats:named-content content-type=\"genus-species\">Neisseria meningitidis<\/jats:named-content>\n                    strain types causing the disease and the potential coverage of disease strains by the newly developed vaccines. This study examined the molecular epidemiology of culture-confirmed IMD cases in Canada by examining the strain types and the potential coverage of a newly licensed 4CMenB vaccine on Canadian serogroup B\n                    <jats:named-content content-type=\"genus-species\">N. meningitidis<\/jats:named-content>\n                    strains. The strain types identified in different parts of Canada appeared to be unique as well as their predicted coverage by the 4CMenB vaccine. These data were compared to data obtained from previous studies done in Canada and elsewhere globally. For effective control of IMD, laboratory surveillance of this type was found to be essential and useful to understand the dynamic nature of this disease.\n                  <\/jats:p>","DOI":"10.1128\/msphere.00883-19","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T09:10:34Z","timestamp":1583226634000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B\n                    <i>Neisseria meningitidis<\/i>\n                    Strains and Their Predicted Coverage by the 4CMenB Vaccine"],"prefix":"10.1128","volume":"5","author":[{"given":"Raymond S. W.","family":"Tsang","sequence":"first","affiliation":[{"name":"Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis K. S.","family":"Law","sequence":"additional","affiliation":[{"name":"Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosita","family":"De Paola","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Giuliani","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Stella","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saul","family":"Deng","sequence":"additional","affiliation":[{"name":"Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Boccadifuoco","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia Monica","family":"Giuliani","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Serino","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/9781555817381.ch34"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.063"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.036"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1507261"},{"key":"e_1_3_2_6_2","unstructured":"Desai S Baclic O Crowcroft N Henry B Rotondo J Tunis M on behalf of the National Advisory Committee on Immunization. 2015. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization\u2019s update on quadrivalent meningococcal vaccines available in Canada. The Public Health Agency of Canada Ottawa Canada. http:\/\/www.healthycanadians.gc.ca\/publications\/healthy-living-vie-saine\/meningococcal-vaccines-quadrivalent-vaccins-meningocoque-2015\/alt\/meningococcal-vaccines-quadrivalent-vaccins-meningocoque-2015-eng.pdf."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30400-6"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1108502"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v40i09a01"},{"key":"e_1_3_2_10_2","unstructured":"Public Health Agency of Canada. 2018. Canada\u2019s provincial and territorial routine (and catch-up) vaccination programs for infants and children. The Public Health Agency of Canada Ottawa Canada. https:\/\/www.canada.ca\/en\/public-health\/services\/provincial-territorial-immunization-information\/provincial-territorial-routine-vaccination-programs-infants-children.html."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne J","year":"1987","unstructured":"Finne J, Bitter-Suermann D, Goridis C, Finne U. 1987. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 138:4402\u20134407.","journal-title":"J Immunol"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.07.084"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2016.1203238"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.01.033"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.03.063"},{"key":"e_1_3_2_16_2","unstructured":"Public Health Agency of Canada. 2018. Notifiable disease online. The Public Health Agency of Canada Ottawa Canada. https:\/\/diseases.canada.ca\/notifiable\/charts?c=pl. Accessed 27 February 2020."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix154"},{"key":"e_1_3_2_18_2","unstructured":"Public Health Ontario. 2018. Reportable disease trends in Ontario meningococcal disease invasive. Public Health Ontario Toronto Canada. https:\/\/www.publichealthontario.ca\/data-and-analysis\/infectious-disease\/reportable-disease-trends-annually#\/37. Accessed 10 July 2019."},{"key":"e_1_3_2_19_2","unstructured":"The Government of New Brunswick. 2016. New Brunswick communicable disease surveillance report 2015. The Government of New Brunswick Fredericton Canada. https:\/\/www.welcomenb.ca\/content\/dam\/gnb\/Departments\/h-s\/pdf\/en\/CDC\/HealthProfessionals\/Annual_Report_CDC_Branch_2015.pdf."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06835-11"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.050369-0"},{"key":"e_1_3_2_22_2","volume-title":"Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU\/EEA","author":"European Centre for Disease Prevention and Control","year":"2017","unstructured":"European Centre for Disease Prevention and Control. 2017. Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU\/EEA. ECDC, Stockholm, Sweden. https:\/\/ecdc.europa.eu\/en\/publications-data\/expert-opinion-introduction-meningococcal-b-4cmenb-vaccine-eueea."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30170-6"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150721"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176177"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00936-09"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.04.015"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00261-17"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.06.021"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.08.006"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1688039"},{"key":"e_1_3_2_32_2","unstructured":"Public Health Agency of Canada. 2014. National Advisory Committee on Immunization (NACI): an advisory committee statement (ACS)\u2014advice for the use of the multicomponent meningococcal serogroup B (4CMenB) vaccine. The Public Health Agency of Canada Ottawa Canada. https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/healthy-living\/meningococcal-serogroup-b-vaccine-advice\/naci-eng.pdf."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.6.3140"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.079921-0"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.26.11.2465-2466.1988"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1013758107"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9202-7_14"},{"key":"e_1_3_2_38_2","unstructured":"Boccadifuoco G. 2015. Re-assessment of MATS ELISA specifications abstr P37. 13th European Meningococcal and Haemophilus Disease Society Meeting Amsterdam The Netherlands."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00202-12"},{"key":"e_1_3_2_40_2","unstructured":"Statistics Canada. 2019. Table\u00a017-10-005-01: population estimates on July 1st in Canada by provinces both sexes. Statistics Canada Ottawa Canada. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710000501&pickMembers%5B0%5D=1.1&pickMembers%5B1%5D=2.1. Accessed on 7 July 2019."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-595"}],"container-title":["mSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mSphere.00883-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mSphere.00883-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T21:15:21Z","timestamp":1695849321000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/mSphere.00883-19"}},"subtitle":[],"editor":[{"given":"Christopher J.","family":"Papasian","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4,29]]}},"alternative-id":["10.1128\/mSphere.00883-19"],"URL":"https:\/\/doi.org\/10.1128\/msphere.00883-19","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737491599.793572431","asserted-by":"object"}]},"ISSN":["2379-5042"],"issn-type":[{"value":"2379-5042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,29]]},"assertion":[{"value":"2019-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00883-19"}}